GlassScriptPhysician profile
Brendan Levy
NPI 1548260474
$7,227.17
in general payments reported to CMS, 2019-2025
37 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $364 · 2021: $1,083 · 2022: $1,829 · 2023: $1,291 · 2024: $1,329 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,772.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,885.63 | 2019-2025 | |
| Gilead Sciences, INC. | $883.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $615.23 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $546.11 | 2020-2025 | |
| Celgene Corporation | $534.46 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $527.86 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $374.74 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $353.71 | 2020-2025 | Entyvio, Gattex |
| Ipsen Biopharmaceuticals, INC | $164.44 | 2024-2025 | Iqirvo |
| Organon LLC | $143.63 | 2023-2024 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $132.11 | 2020-2025 | Ocaliva |
| Redhill Biopharma INC. | $127.56 | 2020-2024 | Talicia |
| Ferring Pharmaceuticals INC. | $116.03 | 2020-2023 | Rebyota |
| Lilly USA, LLC | $105.79 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $84.52 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $78.01 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $71.06 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $59.26 | 2021-2024 | |
| Mauna Kea Technologies, INC. | $45.89 | 2024 | |
| Daiichi Sankyo INC. | $38.46 | 2022 | |
| Qol Medical, LLC | $37.20 | 2021 | |
| Shionogi INC | $34.36 | 2019 | |
| Genzyme Corporation | $23.75 | 2022 | |
| Mylan Institutional INC. | $21.70 | 2023 | Hulio |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2023 | Cyltezo |
| Celltrion USA INC. | $21.39 | 2024 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $20.97 | 2023 | Givlaari |
| Laborie Medical Technologies Corp. | $20.96 | 2024 | Solar Uroflow System |
| Csl Behring | $20.94 | 2019 | |
| Evoke Pharma, INC. | $18.61 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.19 | 2024 | Voquezna |
| Boston Scientific Corporation | $15.84 | 2022 | |
| Braintree Laboratories, INC. | $15.59 | 2024 | Suflave |
| Medtronic, INC. | $15.51 | 2021 | |
| Capsovision, INC. | $13.26 | 2023 | Capsocam Plus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,879.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.